Ondine Biomedical Inc. Launches SurgENTTM for U.S. Chronic Sinus Sufferers

Tuesday, October 9, 2018 Respiratory Disease News
Email Print This Page Comment bookmark
Font : A-A+

SurgENTTM was officially launched during the 64th Annual Meeting of the American Rhinologic Society in Atlanta, GA.

VANCOUVER and ATLANTA, Oct. 09, 2018 /PRNewswire-PRWeb/ -- Ondine Biomedical, Inc.,

an innovative medical solutions company, today announced that they have officially launched their first medical device for the chronic rhinosinusitis (CRS) patient, SurgENTTM, throughout the United States. Ondine presented SurgENT over the weekend during the 64th Annual Meeting of the American Rhinologic Society (ARS) in Atlanta GA.

SurgENT provides a novel approach to sinus irrigation which allows the surgeon, whether in the office or operating room, to dislodge thick secretions and biofilms within the sinus cavities which traditional irrigation has difficulty accomplishing. Effective and thorough removal of sinus secretions diminishes inflammation and improves the quality of life of sinus sufferers. Chronic sinus disease affects millions of people every year and is a major health problem across the globe.

"The ARS meeting was the ideal event to showcase our SurgENT solution to ENT surgeons from across the globe. We are pleased with the encouraging feedback we have been receiving from surgeons and patients alike. "said Michelle Anschuetz, Chief Commercial Officer, Ondine Biomedical, Inc. "As we expand the availability of this innovative sinus irrigation device across the U.S., surgeons will now have an alternative to optimize outcomes for their sinus patients."

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is dedicated to the development of non-antibiotic, anti-infective therapies for a broad-spectrum of bacterial, viral and fungal infections. Ondine's antimicrobial program utilizes a platform technology called photodisinfection, a light-activated approach being developed to provide rapid antimicrobial efficacy and reduced risk of antibiotic resistance. Over 65 patents in 21 patent families have been granted or are pending covering various aspects of the technology. Ondine's flagship nasal photodisinfection system has been deployed in Canada for several years, and other applications of the photodisinfection platform are under development, including Sinuwave™, a photodisinfection product to treat chronic rhinosinusitis, and an endotracheal tube photodisinfection product designed to reduce the incidence of ventilator-associated pneumonia (VAP).

SurgENT is available for sale in the U.S. and Canada. For more information on SurgENT, please visit http://www.ondinebio.com/SurgENT.

About American Rhinologic Society

The American Rhinologic Society's mission is to serve, represent and advance the science and ethical practice of rhinology. The Society promotes excellence in patient care, research and education in Rhinology and Skull Base Disorders. The American Rhinologic Society is dedicated to providing communication and fellowship to the members of the Rhinologic community through on-going medical education, patient advocacy, and social programs. The ARS continuing medical education activities serve to improve professional competence, performance, and promote research.


SOURCE Ondine Biomedical Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store